同宜医药

Toshidun Pharma is a clinical-stage biotechnology company specializing in the development of next-generation bi-specific peptide-drug conjugates (PDCs) for the treatment of solid tumors. The company utilizes its proprietary BEST (Bi-specific Elongated Synergistic Targeting) platform to design therapeutics that simultaneously target two different receptors on tumor cells, enhancing drug delivery precision and reducing systemic toxicity. Its lead candidate, Bi-PDC (CBP-1008), is currently in Phase 2 clinical trials for multiple advanced solid tumors, including ovarian and breast cancers. Toshidun aims to address the limitations of traditional antibody-drug conjugates by leveraging the smaller size and superior tissue penetration of peptides.